Literature DB >> 21680913

The medicalization of sleeplessness: a public health concern.

Mairead Eastin Moloney1, Thomas R Konrad, Catherine R Zimmer.   

Abstract

Sleeplessness, a universal condition with diverse causes, may be increasingly diagnosed and treated (or medicalized) as insomnia. We examined the trend in sleeplessness complaints, diagnoses, and prescriptions of sedative hypnotics in physician office visits from 1993 to 2007. Consistent with the medicalization hypothesis, sleeplessness complaints and insomnia diagnoses increased over time and were far outpaced by prescriptions for sedative hypnotics. Insomnia may be a public health concern, but potential overtreatment with marginally effective, expensive medications with nontrivial side effects raises definite population health concerns.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21680913      PMCID: PMC3134490          DOI: 10.2105/AJPH.2010.300014

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  20 in total

Review 1.  Use of sleep hygiene in the treatment of insomnia.

Authors:  Edward J Stepanski; James K Wyatt
Journal:  Sleep Med Rev       Date:  2003-06       Impact factor: 11.609

2.  Medicalization, markets and consumers.

Authors:  Peter Conrad; Valerie Leiter
Journal:  J Health Soc Behav       Date:  2004

3.  Medicalization and beyond: the social construction of insomnia and snoring in the news.

Authors:  Simon J Williams; Clive Seale; Sharon Boden; Pam Lowe; Deborah Lynn Steinberg
Journal:  Health (London)       Date:  2008-04

4.  Understanding women's sleep management: beyond medicalization-healthicization?

Authors:  Jenny Hislop; Sara Arber
Journal:  Sociol Health Illn       Date:  2003-11

5.  Practice parameters for the nonpharmacologic treatment of chronic insomnia. An American Academy of Sleep Medicine report. Standards of Practice Committee of the American Academy of Sleep Medicine.

Authors:  A L Chesson; W M Anderson; M Littner; D Davila; K Hartse; S Johnson; M Wise; J Rafecas
Journal:  Sleep       Date:  1999-12-15       Impact factor: 5.849

6.  The relationship between insomnia and health-related quality of life in patients with chronic illness.

Authors:  David A Katz; Colleen A McHorney
Journal:  J Fam Pract       Date:  2002-03       Impact factor: 0.493

Review 7.  Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data.

Authors:  G Hajak; W E Müller; H U Wittchen; D Pittrow; W Kirch
Journal:  Addiction       Date:  2003-10       Impact factor: 6.526

Review 8.  Use and abuse of the benzodiazepines.

Authors:  A D Fraser
Journal:  Ther Drug Monit       Date:  1998-10       Impact factor: 3.681

Review 9.  Increased physician-reported sleep apnea: the National Ambulatory Medical Care Survey.

Authors:  Andrew M Namen; Donnie P Dunagan; Alan Fleischer; Janine Tillett; Molly Barnett; W Vaughn McCall; Edward F Haponik
Journal:  Chest       Date:  2002-06       Impact factor: 9.410

10.  Sleep complaints among elderly persons: an epidemiologic study of three communities.

Authors:  D J Foley; A A Monjan; S L Brown; E M Simonsick; R B Wallace; D G Blazer
Journal:  Sleep       Date:  1995-07       Impact factor: 5.849

View more
  45 in total

1.  Trends in Prescribed Central Nervous System Depressant Medications Among Adults Who Regularly Consume Alcohol: United States 1999 to 2014.

Authors:  Jacob T Borodovsky; Melissa J Krauss; Tingying Chi; Laura J Bierut; Richard A Grucza
Journal:  Alcohol Clin Exp Res       Date:  2019-05-28       Impact factor: 3.455

2.  Trends in Insomnia Diagnosis and Treatment Among Medicare Beneficiaries, 2006-2013.

Authors:  Jennifer S Albrecht; Emerson M Wickwire; Aparna Vadlamani; Steven M Scharf; Sarah E Tom
Journal:  Am J Geriatr Psychiatry       Date:  2018-11-02       Impact factor: 4.105

3.  Insomnia, hypnotic drug use, and patient well-being: first, do no harm.

Authors:  Barbara A Phillips
Journal:  Mayo Clin Proc       Date:  2012-05       Impact factor: 7.616

4.  Patient Education and Pharmacist Consultation Influence on Nonbenzodiazepine Sedative Medication Deprescribing Success for Older Adults.

Authors:  Jennifer L Kuntz; Louis Kouch; Daniel Christian; Weiming Hu; Preston L Peterson
Journal:  Perm J       Date:  2019

5.  Barriers and Facilitators to the Deprescribing of Nonbenzodiazepine Sedative Medications Among Older Adults.

Authors:  Jennifer Kuntz; Louis Kouch; Daniel Christian; Preston L Peterson; Inga Gruss
Journal:  Perm J       Date:  2018

6.  Psychological treatment of hypnotic-dependent insomnia in a primarily older adult sample.

Authors:  Kenneth L Lichstein; Sidney D Nau; Nancy M Wilson; R Neal Aguillard; Kristin W Lester; Andrew J Bush; Christina S McCrae
Journal:  Behav Res Ther       Date:  2013-09-26

7.  Sedative-hypnotic medicines and falls in community-dwelling older adults: a cost-effectiveness (decision-tree) analysis from a US Medicare perspective.

Authors:  Cara Tannenbaum; Vakaramoko Diaby; Dharmender Singh; Sylvie Perreault; Mireille Luc; Helen-Maria Vasiliadis
Journal:  Drugs Aging       Date:  2015-04       Impact factor: 3.923

8.  National Trends in Antidepressant, Benzodiazepine, and Other Sedative-Hypnotic Treatment of Older Adults in Psychiatric and Primary Care.

Authors:  Donovan T Maust; Frederic C Blow; Ilse R Wiechers; Helen C Kales; Steven C Marcus
Journal:  J Clin Psychiatry       Date:  2017-04       Impact factor: 4.384

9.  Untreated insomnia increases all-cause health care utilization and costs among Medicare beneficiaries.

Authors:  Emerson M Wickwire; Sarah E Tom; Steven M Scharf; Aparna Vadlamani; Ilynn G Bulatao; Jennifer S Albrecht
Journal:  Sleep       Date:  2019-04-01       Impact factor: 5.849

Review 10.  Sleep: important considerations for the prevention of cardiovascular disease.

Authors:  Michael A Grandner; Pamela Alfonso-Miller; Julio Fernandez-Mendoza; Safal Shetty; Sundeep Shenoy; Daniel Combs
Journal:  Curr Opin Cardiol       Date:  2016-09       Impact factor: 2.161

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.